# Celecoxib ```text DRUG INFORMATION ADULT - • Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 - If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 - For patients ≥10 kg to ≤25 kg the recommended dose is 50 mg twice daily. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 CHILD - Celecoxib capsules are approved for relief of the signs and symptoms of Juvenile Rheumatoid Arthritis in patients 2 years and older. Safety and efficacy have not been studied beyond six months in children. Source: US FDA label for celecoxib (celecoxib), section 'pediatric use', retrieved 2026-08-29 - • Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 - On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 RENAL IMPAIRMENT - The use of celecoxib capsules in patients with severe hepatic impairment is not recommended [ see Dosage and Administration ( 2.6 ) and Clinical Pharmacology ( 12.3 ) ]. 8.7 Renal Insufficiency Celecoxib capsules are not recommended in patients with severe renal insufficiency [ see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) ]. Source: US FDA label for celecoxib (celecoxib), section 'use in specific populations', retrieved 2026-08-29 - Hyperkalemia Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. Source: US FDA label for celecoxib (celecoxib), section 'warnings and cautions', retrieved 2026-08-29 HEPATIC IMPAIRMENT - On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 - On subsequent days, the recommended dose is 200 mg twice daily as needed. 2.7 Special Populations Hepatic Impairment In patients with moderate hepatic impairment (Child-Pugh Class B), reduce the dose by 50%. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 - The use of celecoxib capsules in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 ) ]. Source: US FDA label for celecoxib (celecoxib), section 'dosage and administration', retrieved 2026-08-29 PREGNANCY - Pregnancy category D from 30 weeks of gestation onward. Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved 2026-08-29 - Risk Summary Use of NSAIDs, including celecoxib capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved 2026-08-29 - Avoid use of NSAIDs, including celecoxib capsules, in pregnant women starting at 30 weeks of gestation. Source: US FDA label for celecoxib (celecoxib), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - Infertility Females Based on the mechanism of action, the use of prostaglandin- mediated NSAIDs, including celecoxib capsules, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers', retrieved 2026-08-29 - Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin mediated follicular rupture required for ovulation. Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers', retrieved 2026-08-29 - Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Source: US FDA label for celecoxib (celecoxib), section 'nursing mothers', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)